

Table S1. Kinase inhibitor sensitivity of the CUTC cell lines.

Cell line	Mutation	Drug name	IC50 (nM)
CUTC48	<i>RET/PTC1</i>	Cediranib	667
CUTC48	<i>RET/PTC1</i>	Foretinib	111
CUTC48	<i>RET/PTC1</i>	Lenvatinib	1,525
CUTC48	<i>RET/PTC1</i>	Sorafenib	8,714
CUTC5	<i>BRAF</i> (p.V600E)	Dabrafenib	8
CUTC5	<i>BRAF</i> (p.V600E)	Vemurafenib	859
CUTC5	<i>BRAF</i> (p.V600E)	Selumetinib	195
CUTC5	<i>BRAF</i> (p.V600E)	PD-0325901	18
CUTC5	<i>BRAF</i> (p.V600E)	Trametinib	148
CUTC5	<i>BRAF</i> (p.V600E)	Sorafenib	1,461
CUTC60	<i>BRAF</i> (p.V600E)	Vemurafenib	32,049
CUTC60	<i>BRAF</i> (p.V600E)	Dabrafenib	20,624
CUTC60	<i>BRAF</i> (p.V600E)	Selumetinib	39,505
CUTC60	<i>BRAF</i> (p.V600E)	PD-0325901	9,845
CUTC60	<i>BRAF</i> (p.V600E)	Trametinib	26,725
CUTC60	<i>BRAF</i> (p.V600E)	Sorafenib	1,786
CUTC61	<i>HRAS</i> (p.Q61R)	Vemurafenib	>40,000
CUTC61	<i>HRAS</i> (p.Q61R)	Dabrafenib	>40,000
CUTC61	<i>HRAS</i> (p.Q61R)	Selumetinib	31,549
CUTC61	<i>HRAS</i> (p.Q61R)	PD-0325901	1,461
CUTC61	<i>HRAS</i> (p.Q61R)	Trametinib	5,467
CUTC61	<i>HRAS</i> (p.Q61R)	Sorafenib	9,554